4NL Muller,DA White,H Jiang et al.Diagnosis and management of drug-associated interstitial lung disease[J].Br J Cancer,2004,91 (Suppl 2):S24 -S30.
5Onn A,Tsuboi M,Thatcher N.Treatment of nonsmall-cell lung cancer:a perspective on the recent advances and the experience with gefitinib[J].Br J Cancer,2004,91 (Suppl 2):S11-17.
二级参考文献8
1[1]Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target - based anticancer agents[J]. Drugs ,2000,60(Suppl) :S1 - S14.
2[2]Hanahan D, Weinberg RA. The hallmarks of cancer [ J ]. Cell,2000,100(1 ): 57 - 70.
3[3]Baselga J. New therapeutic agents targeting the epidermal growth factor receptor[J]. J Clin Oncol,2000,18(Suppl 21) :S54 - S59.
4[4]Wells A. EGF receptor[J]. Int J Biochem Cell Biol, 1999,31(6): 637 - 643.
5[5]Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signaling on the surface of living cell [J ]. Nat Cell Biol,2002,2(3): 168 - 172.
6[6]Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions[ J ]. FEBS Lett, 1997,410 ( 1 ): 83 - 86.
7[7]Riese DJ, Stem DF. Specificity within the EGF family/ErbB receptor family signaling network[ J ]. BioasSays, 1998,20( 1 ) :41 - 48.
8[8]Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Clin Cancer Res, 2001,7(10): 1459 - 1465.
